

Gail Roboz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2578682/publications.pdf>

Version: 2024-02-01

12
papers

1,325
citations

932766

10
h-index

1199166

12
g-index

12
all docs

12
docs citations

12
times ranked

1229
citing authors

#	ARTICLE	IF	CITATIONS
1	2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. <i>Blood</i> , 2021, 138, 2753-2767.	0.6	305
2	Eprenetapopt (APR-246) and Azacitidine in <i>TP53</i> -Mutant Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2021, 39, 1584-1594.	0.8	278
3	Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. <i>Blood</i> , 2020, 135, 463-471.	0.6	266
4	Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study. <i>Blood</i> , 2020, 136, 674-683.	0.6	144
5	Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML. <i>Blood Advances</i> , 2020, 4, 1894-1905.	2.5	129
6	Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2021, 39, 3737-3746.	0.8	90
7	Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status. <i>Blood</i> , 2022, 139, 2145-2155.	0.6	38
8	A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD mutant acute myeloid leukemia. <i>Blood Advances</i> , 2020, 4, 1711-1721.	2.5	30
9	BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cells. <i>Blood</i> , 2021, 137, 812-825.	0.6	18
10	Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy. <i>Blood</i> , 2022, 140, 285-289.	0.6	15
11	Geriatric assessment for older adults receiving less-intensive therapy for acute myeloid leukemia: report of CALGB 361101. <i>Blood Advances</i> , 2022, 6, 3812-3820.	2.5	9
12	Harnessing the Therapeutic Value of Venetoclax: A Breakthrough Therapy in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2021, 39, 2742-2748.	0.8	3